CoChat

Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement: A Randomized, Double-Blind, Placebo-Controlled Trial

Heit, John A., Elliott, C. Gregory, Trowbridge, Arthur A., Morrey, Bernard F., Gent, Michael, Hirsh, Jack, for the Ardeparin Arthroplasty Study Group* · 2000 · Annals of Internal Medicine
Cited by 132

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The optimal duration of prophylaxis against venous thromboembolism after total hip or knee replacement is uncertain. OBJECTIVE: To determine the efficacy and safety of extended out-of-hospital prophylaxis with low-molecular-weight heparin (ardeparin sodium). DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: 33 community, university, or university-affiliated hospitals. PATIENTS: 1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative ardeparin prophylaxis. INTERVENTION: Daily subcutaneous ardeparin (100 anti-Xa IU/kg of body weight) or placebo from time of hospital discharge to 6 weeks after surgery. MEASUREMENTS: Symptomatic, objectively documented venous thromboembolism or death, along with major bleeding, from time of hospital discharge to 12 weeks after surgery. RESULTS: Patients who received ardeparin (n = 607) and those who received placebo (n = 588) did not differ significantly in the cumulative incidence of venous thromboembolism or death (9 cases [1.5%] compared with 12 cases [2.0%]; odds ratio, 0.7 [95% CI, 0.3 to 1.7]; P > 0.2; absolute difference, -0.56 percentage points [CI, -2.2 to 1.1 percentage points]) or major bleeding (2 cases [0.3%] compared with 3 cases [0.5%]). CONCLUSIONS: Among patients who had total knee or total hip replacement and received 4 to 10 days of postoperative ardeparin prophylaxis, the cumulative incidence of symptomatic venous thromboembolism or death after hospital discharge was not significantly reduced by extended out-of-hospital ardeparin prophylaxis. Extended ardeparin use could provide a maximum 2.2-percentage point true reduction in such events. The benefit of extended ardeparin use is not clinically important for most patients. Future research should identify high-risk patients who would benefit most from extended prophylaxis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-132-11-200006060-00002

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 14

  1. 10.1378/chest.114.5_Supplement.531S · DOI · Paper page
  2. 10.1016/S0140-6736(96)01453-5 · DOI · Paper page
  3. 10.1055/s-0038-1655901 · DOI
  4. 10.1056/NEJM199609053351002 · DOI · Paper page
  5. 10.1016/S0049-3848(98)00018-8 · DOI
  6. 10.1001/archinte.158.8.873 · doi:10.1001/archinte.158.8.873
  7. 10.1001/jama.1990.03440200057023 · DOI · Paper page
  8. Mantel N, 1959, J Natl Cancer Inst, 22, 719
  9. 10.1001/archinte.160.5.669 · doi:10.1001/archinte.160.5.669
  10. Francis CW, 1986, Clin Orthop, 232, 271
  11. 10.7326/0003-4819-127-6-199709150-00004 · DOI · Paper page
  12. 10.2106/00004623-199408000-00008 · DOI
  13. 10.1055/s-0038-1655902 · DOI
  14. 10.1055/s-0037-1614410 · DOI

Cited by

See all 132

Metadata

Authors
Heit, J. A., Elliott, C. G., Trowbridge, A. A., Morrey, B. F., Gent, M., Hirsh, J., & for the Ardeparin Arthroplasty Study Group*
Venue
Annals of Internal Medicine
Published
2000-06-06
Volume
132
Issue
11
Pages
853-861
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2050580617
Cited by
132
References
1
FWCI
8.97
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-132-11-200006060-00002
The paper
Heit, J. A., Elliott, C. G., Trowbridge, A. A., Morrey, B. F., Gent, M., Hirsh, J., & for the Ardeparin Arthroplasty Study Group*. (2000). Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-132-11-200006060-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.